a randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections

Tiklamalar: 245
ID: 223314
2015
Ucretsiz PDF
Makale Kalitesi ve Performans Metrikleri
Genel Kalite
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
Yapay Zeka Kalite Degerlendirmesi
Analiz edilmedi
Readership in this journal
Steady

Ranked #84 of 169 articles by views in israel journal of chemistry

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 169 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Ozet
Background: A randomized, double-blind, multicenter trial was done to compare two doses of delafloxacin with tigecycline in patients with various complicated skin and skin-structure infections (wound infections following surgery, trauma, burns, or animal/insect bites, abscesses, and cellulitis). Methods: Patients were randomized 1:1:1 to receive delafloxacin 300 mg intravenous (IV) every 12 h, delafloxacin 450 mg IV every 12 h, or tigecycline 100 mg IV × 1, followed by 50 mg IV every 12 h; randomization was stratified by infection type. Duration of therapy was 5–14 days. The primary efficacy analysis, performed on the clinically evaluable (CE) population at the test-of-cure (TOC) visit (14–21 days after the final dose of study drug), compared clinical response rates in the delafloxacin and tigecycline arms. Clinical response rates in the two delafloxacin arms were also compared. Results: Among CE patients, clinical cure rates at TOC visit were similar in the delafloxacin and tigecycline arms (94.3%, 92.5%, and 91.2%, respectively in delafloxacin 300-mg, delafloxacin 450-mg, and tigecycline arms). Overall, the most frequent adverse events were nausea, vomiting, and diarrhea; the 300-mg delafloxacin arm was the best-tolerated regimen. Conclusions: Delafloxacin was similarly effective as tigecycline for a variety of complicated skin and skin-structure infections and was well tolerated. (Clinicaltrials.gov NCT 0719810)
Referans Anahtari
oriordan2015internationala Kullanarak makale yazarken otomatik alinti icin bu anahtari kullanin SciMatic Makale Yoneticisi veya Tez Yoneticisi
Yazarlar ;William O’Riordan;Purvi Mehra;Paul Manos;Jeff Kingsley;Laura Lawrence;Sue Cammarata
Dergi israel journal of chemistry
Yil 2015
DOI
10.1016/j.ijid.2014.10.009
URL
http://www.sciencedirect.com/science/article/pii/S1201971214016555
Anahtar Kelimeler
mrsa mssa

Atiflar

Atif bulunamadi. Atif eklemek icin yoneticiyle iletisime gecin: info@scimatic.org

Yorumlar

Henuz yorum yok. Bu makaleye ilk yorumu siz yapin.